Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125694221 | 12569422 | 1 | I | 201602 | 20160714 | 20160719 | 20160719 | PER | US-PFIZER INC-2016346581 | PFIZER | 53.00 | YR | F | Y | 66.00000 | KG | 20160719 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125694221 | 12569422 | 1 | PS | RAPAMUNE | SIROLIMUS | 1 | Oral | 0.5 MG, DAILY (1 TABLET DAILY) | 21110 | .5 | MG | TABLET | |||||||
| 125694221 | 12569422 | 2 | SS | RAPAMUNE | SIROLIMUS | 1 | 0.5 MG, 3X/DAY | 21110 | .5 | MG | TABLET | TID | |||||||
| 125694221 | 12569422 | 3 | C | VALACYCLOVIR | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | UNK UNK, 2X/DAY | 0 | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125694221 | 12569422 | 1 | Stem cell transplant |
| 125694221 | 12569422 | 3 | Stem cell transplant |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125694221 | 12569422 | Drug level decreased | |
| 125694221 | 12569422 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125694221 | 12569422 | 1 | 201312 | 0 | ||
| 125694221 | 12569422 | 3 | 2010 | 0 |